EICHOR
● Recruiting
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Condition: Osteosarcoma · Ewing Sarcoma · Sponsor: Milton S. Hershey Medical Center
About this study
Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional therapy and/or maintenance therapy we hope to safely observe improved event-free survival and overall survival. There are 5 cohorts covered under this master protocol.
This description comes directly from the study's public registry record.
Talk to the study team
BCC Enroll · 7175310003 · BCCEnroll@pennstatehealth.psu.edu
Always discuss trial participation with your own doctor first.
Locations (2)
| St. Joseph's Children's Hospital | Tampa, Florida, United States | Recruiting |
| Penn State Milton S. Hershey Medical Center and Children's Hospital | Hershey, Pennsylvania, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07321912